UBS Group Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group (NYSE:MD) had its price target lifted by stock analysts at UBS Group from $10.50 to $16.50 in a report issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price target points to a potential upside of 6.80% from the stock’s current price.

Several other analysts also recently commented on the company. Jefferies Financial Group upped their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft upped their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Stock Performance

Shares of NYSE MD traded up $0.31 during trading hours on Tuesday, reaching $15.45. The stock had a trading volume of 402,319 shares, compared to its average volume of 870,622. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -5.05, a PEG ratio of 2.36 and a beta of 1.55. The company has a current ratio of 1.58, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $15.52. The firm has a 50-day moving average of $11.70 and a 200-day moving average of $9.45.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 EPS. Equities research analysts predict that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Insider Activity at Pediatrix Medical Group

In related news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,100 shares of company stock valued at $701,889 in the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of large investors have recently bought and sold shares of MD. BNP Paribas Financial Markets grew its holdings in Pediatrix Medical Group by 79.2% during the 1st quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock valued at $419,000 after buying an additional 18,438 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Pediatrix Medical Group by 8.2% during the first quarter. Empowered Funds LLC now owns 235,124 shares of the company’s stock worth $2,358,000 after purchasing an additional 17,784 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Pediatrix Medical Group by 4.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 72,767 shares of the company’s stock worth $730,000 after purchasing an additional 3,142 shares during the last quarter. Illinois Municipal Retirement Fund boosted its holdings in shares of Pediatrix Medical Group by 8.8% during the first quarter. Illinois Municipal Retirement Fund now owns 49,526 shares of the company’s stock worth $497,000 after purchasing an additional 4,013 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after purchasing an additional 1,167 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.